SeaStarMedical @SeaStarMedical Twitter profile

Last Seen Profiles

@RenniesLanding

@NottsCC

@MSapulete21524

@maude_story771

@SheSoShy3

@luvmysubs

@vTopTier

@tylerjowalker

@lsgh1959

@isarpishan

@UsmanWorld

@ValentinaE62757

@forneybsb17

@tangamapia

@Zwidyzwidy

@a_a_skz

@soma_12_21

@AsSa66986762

@gamscout

@hop3less

@AllenWoods37691

@maude_story771

@TomGaymor

@maude_story771

@2exsi

@FL_FirstsLove

@bosss_un

@ttxuorr

@dfo7E2Ur9hLR0XR

@PriscillaL1978

@VGarcia_AHS

@aliciawlin

@WayoftheRay

@DisneyChannel

@kiddcashx2

@UsmanWorld

SeaStarMedical

@SeaStarMedical

2 years

We are excited to announce that Dr. Kevin Chung will join SeaStar Medical as Chief Medical Officer, effective July 1, 2022. Dr. Chung is a renowned critical care physician and expert in extracorporeal life support therapies. Read more at

14

4

102

SeaStarMedical

@SeaStarMedical

8 months

PRESS RELEASE: FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury Read the full release HERE: #medicalnews #PressRelease #medicaldevice $ICU

FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic...

SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune™ product family DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical...

investors.seastarmedical.com

18

28

93

SeaStarMedical

@SeaStarMedical

8 months

Here’s a short video of what we’re fighting against in acute kidney injury here at SeaStar Medical. Next week, we’ll show you what we’re doing about it….stay tuned! #Healthcare #AKI #SeaStar $ICU

SeaStar Medical Acute Kidney Injury (AKI) Mechanism of Disease

Video explaining the mechanism of disease for Acute Kidney Injury (AKI), brought to you by SeaStar Medical

www.youtube.com

22

24

84

SeaStarMedical

@SeaStarMedical

8 months

Big news from the Big Apple – read more from the official @US_FDA website HERE: Thank you @nasdaq for the great shot! #fdaapproval #nasdaq #icu $ICU

18

24

78

SeaStarMedical

@SeaStarMedical

8 months

Watch the exciting and informative interview from our fearless leader, CEO Eric Schlorff @SchlorffEric as he discusses SeaStar Medical on the Big Biz Show! @sullyontheair @sullyspeaks @biztv @biztalkradio @youtooamerica

7

16

58

SeaStarMedical

@SeaStarMedical

8 months

It’s been a big week here at SeaStar Medical! In addition to the approval of our Quelimmune (SCD-Pediatric) device, we’ve also published a significant manuscript highlighting the robust capabilities of this novel technology: Stu Goldstein’s @slgold777 paper showcasing the pooled

21

10

56

SeaStarMedical

@SeaStarMedical

8 months

Last week, we shared what we’re fighting against in acute kidney injury here at SeaStar Medical – this week, we’re excited to share how we are combating this harmful disease with the Selective Cytopheretic Device (SCD). LINK: #healthcare #AKI

SeaStar Medical SCD Mechanism of Action

Video explaining the mechanism of action for SeaStar Medical's Selective Cytopheretic Device (SCD)

www.youtube.com

17

10

52

SeaStarMedical

@SeaStarMedical

5 months

SeaStar CEO, @SchlorffEric appears on the Big Biz Show to discuss our SCD technology and progress we're making to commercialize the QUELimmune pediatric device! Big things ahead!! #SCD $ICU #ICU @SullyOnTheAir

4

14

49

SeaStarMedical

@SeaStarMedical

8 months

PRESS RELEASE: Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure Read the full release HERE: #pressrelease #medicalnews

Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients...

Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) - SeaStar...

investors.seastarmedical.com

3

8

47

SeaStarMedical

@SeaStarMedical

8 months

In this newly published paper, led by Dr. Jeffrey Dellavolpe and team, read about the role our SCD played in a groundbreaking sequential extracorporeal treatment strategy of a 28-year-old patient who developed streptococcal toxic shock syndrome with multi-organ failure.

21

14

49

SeaStarMedical

@SeaStarMedical

2 years

We welcome @chungk1031 as Chief Medical Officer of SeaStar Medical. His 20+ years as a critical care physician with expertise in extracorporeal life support therapies (ECLS) will help drive higher standards of care for critically ill patients. Welcome to SeaStar Medical, Kevin.

0

4

45

SeaStarMedical

@SeaStarMedical

1 year

PRESS RELEASE: FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients Read the full release HERE: #seastar #medical #pressrelease #pediatrics #biotech #ICU $ICU

FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric...

DENVER, Oct. 30, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune...

investors.seastarmedical.com

10

16

42

SeaStarMedical

@SeaStarMedical

7 months

PRESS RELEASE: SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients Read the full release HERE: #MedTwitter #SCDPED #AKI #ICU $ICU

SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial...

Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company...

investors.seastarmedical.com

5

13

39

SeaStarMedical

@SeaStarMedical

7 months

SeaStar is a proud sponsor of the 6th CKD Drug Development Summit, taking place March 19-21 in Boston. The CKD Summit is the premier forum bringing together key opinion leaders, industry partners and regulators focusing on the next generation of drug development in kidney

4

16

42

SeaStarMedical

@SeaStarMedical

6 months

SeaStar Medical is proud to be a sponsor and presenter at the 2nd International Conference on Extracorporeal Organ Support in Zagreb, Coatia. Our CMO, Dr. Kevin Chung @chungk1031 will be chairing "The Selective Cytophertic Device - Where are We in 2024?" on Thursday, April 25th.

5

7

42

SeaStarMedical

@SeaStarMedical

11 months

We are thrilled to announce that our very own Chief Medical Officer, Dr. Kevin Chung, has been included in the Most Innovative Chief Medical Officers to Follow in 2023 by Insights Care Magazine. Read the full article here: @chungk1031 #ICU

Kevin Chung: Pioneering Innovative Solutions in Critical Care

A fearless and competent medical professional, Kevin Chung has been serving the critical care industry for more than a decade.

insightscare.com

1

9

40

SeaStarMedical

@SeaStarMedical

7 months

Join us next week, Wednesday, March 13th at the 29th International Conference on Advances in Critical Care Nephrology to learn more about our innovative Quelimmune (SCD-Pediatric) device and its role as an impactful new therapy in pediatric acute kidney injury. Register now at

7

14

39

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury Link: #ICU #SeaStar #Hyperinflammation #CellDirectedTherapy #FDA #Kidney $ICU

SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce...

Patient e nrollment in pivotal clinical study expected to begin in March DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) - SeaStar Medical (Nasdaq: ICU), a medical device company developing proprietary...

investors.seastarmedical.com

3

10

34

SeaStarMedical

@SeaStarMedical

5 months

More great news about the potential of the SCD! A new manuscript now online summarizing 4 pediatric & adult cases where SCD technology assisted in the transition of patients to successful organ transplant or device implantation. #SCD #ICU #MedTwitter ()

7

5

33

SeaStarMedical

@SeaStarMedical

7 months

Read now: a recent article in @renalandurology on the long-term consequences in children with severe AKI requiring CKRT citing data from the @WeROCK_Team registry and other studies. The article mentions the recent HDE approval of Quelimmune Pediatric in pediatric AKI due to

2

13

34

SeaStarMedical

@SeaStarMedical

1 year

PRESS RELEASE: FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome #PressRelease #ICU $ICU

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for...

DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...

investors.seastarmedical.com

1

11

32

SeaStarMedical

@SeaStarMedical

7 months

Join SeaStar Medical's Industry Lunch Symposium webcast from the AKI & CRRT 2024 Conference today! - the livestream will begin at 3:30ET/12:30PT #kidney #AKI #SCD #MedTwitter #ICU

AKI-CRRT Symposium - SeaStar Medical

AKI & CRRT Symposium 2024

seastarmedical.com

5

7

31

SeaStarMedical

@SeaStarMedical

2 years

It’s official! Our NEUTRALIZE-AKI study to evaluate the SCD in critically ill adults with AKI is on . We are working with clinical sites & look forward to our first patient. #celldirectedtherapy #aki #CriticalCare #Hyperinflammation #ClinicalTrials $ICU

0

8

27

SeaStarMedical

@SeaStarMedical

3 months

A very big day in pediatric AKI, today we announce the FIRST pediatric patient is treated with our QUELIMMUNE therapy!

First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved...

DENVER, July 23, 2024 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setting with QUELIMMUNE™, its U.S....

investors.seastarmedical.com

5

6

29

SeaStarMedical

@SeaStarMedical

6 months

Here’s a brief video from the European Journal of Heart Failure showcasing the role of inflammation and innate immunity in heart failure and the potential of our SCD technology in helping treat severe heart failure patients' transition to LVAD. This will be studied in a clinical

4

7

30

SeaStarMedical

@SeaStarMedical

3 months

Did you hear the BIG NEWS??? First commercial sale of QUELIMMUNE!!! This was a HUGE endeavor, and we're finally here! Thanks to all involved! #ICU $ICU

1

3

30

SeaStarMedical

@SeaStarMedical

5 months

SeaStar Medical CEO @SchlorffEric was recently interviewed in a Signals Expert Q&A on kidney disease device innovation. Read more here: #ICU $ICU #nephtwitter #SCD #CKRT

Expert Q&A: Bringing New Devices To Market In Kidney Failure (ESKD)

How 6 device leaders think about progress, pitfalls, and potential in this space

trfitzpatrick.com

6

7

28

SeaStarMedical

@SeaStarMedical

9 months

Will you be at next week’s SCCM Critical Care Congress, Jan 21-23 in Phoenix, AZ? SeaStar’s own @chungk1031 and @SaiIyerPhD will be there…. Let’s meet up! #SCCM2024 #SeaStarMedical

3

8

28

SeaStarMedical

@SeaStarMedical

10 months

SeaStar Medical will be holding investment community meetings Jan. 8-11 at J.P. Morgan Healthcare week in San Francisco. Join CEO, Eric Schlorff @SchlorffEric and CMO Kevin Chung, MD. @chungk1031 For more information, contact Jody Cain at LHA Investor Relations: JCain @lhai .com

5

8

28

SeaStarMedical

@SeaStarMedical

9 months

PRESS RELEASE: SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications Read the full press release HERE:

SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic...

DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...

investors.seastarmedical.com

3

6

27

SeaStarMedical

@SeaStarMedical

7 months

Today, we’re summarizing a new review showcasing the recent advances in enrichment strategies and sub-phenotyping in sepsis-associated acute kidney injury (SA-AKI) trials. Our #CMO , @chungk1031 , was among the authors on this paper. Link:

3

5

27

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical CMO Kevin Chung to present on Feb. 28 at the 39th Annual Children’s National Symposium ECMO Conference on Extracorporeal Cell Directed Therapy: Targeting the cytokine storm at the source. More at #keystoneECMO #AKI #Hyperinflammation $ICU

1

6

25

SeaStarMedical

@SeaStarMedical

1 year

"SeaStar Medical Gets Third Breakthrough Nod for Selective Cytopheretic Device" - view the full article on BioWorld HERE: #mednews #bioworld #medtech #ICU $ICU

Seastar gets third breakthrough nod for Selective Cytopheretic device

Seastar Medical Holding Corp. was granted a third breakthrough device designation by the U.S. FDA for its Selective Cytopheretic device (SCD), a biomimetic membrane-based device used to treat...

www.bioworld.com

3

15

26

SeaStarMedical

@SeaStarMedical

1 year

PRESS RELEASE: FDA Grants Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device for Cardiorenal Syndrome LINK: #PressRelease #medicaldevices #ICU $ICU

FDA Grants Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device for...

DENVER, Sept. 29, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...

investors.seastarmedical.com

5

14

25

SeaStarMedical

@SeaStarMedical

6 months

Every day in the US, more than 200 children are diagnosed with severe sepsis. April 21-27 is Pediatric Sepsis Week! Learn more at For more information on SeaStar Medical's efforts in Pediatric acute kidney injury due to Sepsis, visit

3

5

25

SeaStarMedical

@SeaStarMedical

1 year

"SCD Treatment for Severe AKI Pediatric Patients Shows Promise" - read the full article from Cincinnati Children's Hospital at the link below: #mednews #Pediatrics #AKI #ICU $ICU

0

14

25

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit Link: @KidneyDD_Series #ICU #SeaStar #Hyperinflammation #CellDirectedTherapy #Kidney $ICU

SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease...

DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...

investors.seastarmedical.com

2

6

21

SeaStarMedical

@SeaStarMedical

9 months

PRESS RELEASE: SeaStar Medical Appoints David A. Green as Chief Financial Officer - read the full press release HERE:

SeaStar Medical Appoints David A. Green as Chief Financial Officer

DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...

investors.seastarmedical.com

1

7

23

SeaStarMedical

@SeaStarMedical

1 year

Join us at the world’s premier nephrology meeting as we present 3 posters showcasing our selective cytopheretic device (SCD): Poster 135: a case series of patients with hepatorenal syndrome successfully treated with the SCD. Poster 136: a comprehensive summary of safety from 6

13

4

22

SeaStarMedical

@SeaStarMedical

1 year

PRESS RELEASE: SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption LINK: #PressRelease #medicaldevices #ICU $ICU

SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric...

Com pany to finalize labeling with FDA Approv able Letter expected within a month DENVER, Oct. 03, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company...

investors.seastarmedical.com

1

12

21

SeaStarMedical

@SeaStarMedical

1 year

Today we are excited to share a manuscript recently published in Blood Purification about our pediatric selective cytopheretic device (SCD) in hemolytic uremic syndrome-induced AKI. @Rhodeshambrick @slgold777 @DDD_Askenazi (1 of 9) #tweetorial #AKI $ICU

1

10

21

SeaStarMedical

@SeaStarMedical

1 year

SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective Cytopheretic Device in Critically Ill Adults with Acute Kidney Injury #ICU $ICU #hyperinflammation #celldirectedtherapy #kidney #NEUTRALIZEAKI

SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective...

DENVER, April 19, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...

investors.seastarmedical.com

1

6

21

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury #hyperinflammation #celldirectedtherapy #ICU #Kidney #AKI $ICU

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically...

The NEUTRALIZE-AKI study will evaluate safety and efficacy of the SCD ’s ability to target and neutralize the highly activated proinflammatory neutrophils and monocytes that drive hyperinflammation...

investors.seastarmedical.com

1

8

21

SeaStarMedical

@SeaStarMedical

2 years

Yesterday, CMO Kevin Chung presented "Extracorporeal Cell Directed Therapy: Targeting the cytokine storm at the source" to leading experts of #ECMO Advanced Therapies for Cardiac & Respitory Failure. More at #KeystoneECMO #Hyperinflammation #ICU $ICU

0

5

19

SeaStarMedical

@SeaStarMedical

1 year

Mortality rates in children with AKI and multi-organ dysfunction requiring continuous kidney replacement therapy (CKRT) continues to approach 50%. (Goldstein, et al. KI Reports. 2021). SeaStar Medical is fighting to change these outcomes- more at $ICU #AKI

Fighting the Cytokine Storm | SeaStar Medical

SeaStar Medical is advancing the science of immunomodulation to prevent the devastation of a cytokine storm

seastarmedical.com

0

8

19

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical Chief Medical Officer Dr. Kevin Chung to Discuss Design Considerations for Clinical Trials at Kidney Disease Clinical Trialists (KDCT) Summit (March 3 - 4). More at #AKI #KDCTmeeting #ICU $ICU

KDCT Workshop 2025 - Landing

KDCT 2025 Workshop: April 4-5, 2025

www.kdctmeeting.com

2

7

19

SeaStarMedical

@SeaStarMedical

2 years

See @BioWorld MedTech's story abt FDA approval of pivotal SCD study. It will demonstrate the efficacy of SCD in reducing #hyperinflammation in #AKI patients requiring #CKRT . Approx 6 mil Americans diagnosed with AKI each year, & 200k require CKRT. $ICU

0

8

19

SeaStarMedical

@SeaStarMedical

1 year

Congratulations to @aakashdeeparora & @slgold777 for a tremendous #CCNCLondon2023 meeting last week. It was an honor for SeaStar Medical to be a part of this very special event!

2

7

17

SeaStarMedical

@SeaStarMedical

1 year

Next in our video series, Dr. David Humes walks us through the process of integrating the selective cytopheretic device into a standard CKRT circuit. The SCD can be seamlessly integrated into existing workflows with CKRT machines in the ICU.

0

4

18

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical is excited to announce that we're attending the #AKICRRT23 conference in San Diego, CA. Visit us at Booth 8 in the Marriott Grand Ballroom & say hello! #hyperinflammation #celldirectedtherapy #ICU #Kidney #AKI $ICU

0

5

18

SeaStarMedical

@SeaStarMedical

1 year

PRESS RELEASE: First Patient Enrolled in SeaStar Medical’s Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury Read the full release here: #pressrelease #medicaldevices #clinicaltrials #medtech #ICU $ICU

First Patient Enrolled in SeaStar Medical’s Pivotal Clinical Trial with the Selective Cytopheretic...

DENVER, June 20, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...

investors.seastarmedical.com

0

6

18

SeaStarMedical

@SeaStarMedical

10 months

PRESS RELEASE: SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts Read the full press release HERE: #PressRelease #ICU $ICU

SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical...

DENVER, Dec. 13, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune...

investors.seastarmedical.com

0

5

18

SeaStarMedical

@SeaStarMedical

6 months

Listen to our CEO Eric Schlorff @SchlorffEric describe how SeaStar Medical is redefining extracorporeal therapies and working to reduce the consequences of dysregulated inflammation on vital organs during the Noble Capital Markets Virtual Healthcare Conference

11

4

17

SeaStarMedical

@SeaStarMedical

2 years

How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms @MedTechDaily Thank you, @jameshammerand

How SeaStar's device calms hyperinflammation — and could prevent lasting damage from COVID cytokine...

SeaStar Medical won FDA breakthrough device designation for technology that could help prevent chronic conditions for COVID-19 patients.

www.medicaldesignandoutsourcing.com

2

9

17

SeaStarMedical

@SeaStarMedical

4 months

We are excited to take part in the 42nd Vicenza Course on AKI-CRRT-ECOS & Critical Care Nephrology next week in Vicenza, Italy! SCD Inventor, Dr. David Humes will give a talk on the development of our SCD therapy, pediatric data leading to approval of QUELIMMUNE, and our work in

20

5

17

SeaStarMedical

@SeaStarMedical

1 year

Watch Dr. David Humes recount his original clinical study that led to the discovery of the selective cytopheretic device and the mechanism of action of how it works #MedTwitter #ICU $ICU

Background and MOA of SCD

Dr. David Humes recounts his original clinical study that led to the serendipitous discovery of the selective cytopheretic device and the mechanism of action...

www.youtube.com

0

5

16

SeaStarMedical

@SeaStarMedical

4 months

New article in Nature Scientific Reports describes the mechanism of action of our novel SCD technology in combating the harmful effects of hyperinflammation. Take a👀. . .

15

6

16

SeaStarMedical

@SeaStarMedical

3 months

We are now enrolling in our SAVE (SCD-PED) Pediatric Surveillance Registry!! Learn more here:

5

4

14

SeaStarMedical

@SeaStarMedical

1 year

SeaStar Medical is proud to be a Platinum Sponsor of the First International Conference of Critical Care Nephrology in Children, taking place July 27-29 in London, UK #CriticalCare #MedTwitter $ICU #CCNC

1

7

15

SeaStarMedical

@SeaStarMedical

2 years

Excited for our own @chungk1031 to participate in Hearts for Health Virtual Shadowing session today.

1

4

15

SeaStarMedical

@SeaStarMedical

1 year

DID YOU KNOW: Patients with AKI stay in the ICU twice as long, 8 days vs. 4 days (DeZan F, et al. Blood Purif. 2020). Find out how SeaStar Medical is fighting to change these outcomes in pediatric patients at #medicaldevices #icu #kidneydisease $ICU

Fighting the Cytokine Storm | SeaStar Medical

SeaStar Medical is advancing the science of immunomodulation to prevent the devastation of a cytokine storm

seastarmedical.com

0

6

13

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement #icu $icu #celldirectedtherapy #hyperinflammation

SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private...

DENVER, March 16, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...

investors.seastarmedical.com

6

4

15

SeaStarMedical

@SeaStarMedical

2 years

If you're at AKI & CRRT 2023 #AKICRRT23 , don't miss our poster presentations. Read more about SeaStar Medical at #ICU #Hyperinflammation #celldirectedtherapy #kidney #ICU $ICU

1

6

15

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical CEO Eric Schlorff and CMO Kevin Chung to present at the Emerging Growth Virtual Conference on Wed, March 22, 2023 at 2:15 p.m. ET. To attend and submit questions register at . @chungk1031 #ICU $ICU #celldirectedtherapy

0

7

15

SeaStarMedical

@SeaStarMedical

2 years

Join Us! SeaStar Medical Lunch Symposium at AKI &CRRT in San Diego, CA #AKICRRT23 $ICU #ICU #celldirectedtherapy #hyperinflammation

1

4

15

SeaStarMedical

@SeaStarMedical

1 year

Today, we’re sharing another tweetorial of a pediatric case report published by Dr. Stu Goldstein & colleagues showcasing another successful example of the selective cytopheretic device (SCD) in action. (1 of 11) #tweetorial #ICU $ICU

1

7

15

SeaStarMedical

@SeaStarMedical

1 year

At SeaStar Medical, we are fighting the effects of a dysregulated immune response. Here’s a closer look at how our novel Selective Cytopheretic Device (SCD) deactivates inflammatory neutrophils & monocytes to restore immune balance. #MedDevice #ICU $ICU

0

7

14

SeaStarMedical

@SeaStarMedical

11 months

Today, we’re excited to share another important journal article that was recently published in Critical Care Explorations; this paper summarizes the robust safety profile of the selective cytopheretic device (SCD) in critically ill patients. (1/8) #MedTwitter #criticalcare $icu

2

4

14

SeaStarMedical

@SeaStarMedical

1 year

This week, our Chief Medical Officer and retired Army physician, Dr. Kevin Chung, MD, spoke at the session "Cellular Therapeutics for Treatment of Shock and Trauma at the Military Health System Research Symposium" (MHSRS) about the life-saving potential of our SCD device #MHSRS

0

8

12

SeaStarMedical

@SeaStarMedical

1 year

Learn how our Selective Cytopheretic Device (SCD) modulates immune effector cells responsible for a dysregulated immune response. #MedTech #MedDevice #SCD #AKI #ICU $ICU

0

7

11

SeaStarMedical

@SeaStarMedical

1 year

1/7 SeaStar Medical is proud to announce that a pre-print manuscript of the clinical safety of the selective cytopheretic device (SCD) in AKI is now available on at the link HERE: #ClinicalTrials #AKI #medicaldevices $ICU (con't)

Authorea

Authorea is the leading platform to write, cite, collaborate, host data, and publish.

www.authorea.com

2

8

12

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI) #SeaStar #ICU #Hyperinflamation #CellDirectedTherapy #Kidney Link:

0

3

13

SeaStarMedical

@SeaStarMedical

1 year

PRESS RELEASE: SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update Read the full release HERE: #PressRelease #icu $ICU

SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update

Management to hold a b usiness u pdate c onference c all on August 2 2 beginning at 4 :00 p.m. Eastern time DENVER, Aug. 14, 2023 (GLOBE NEWSWIRE) - SeaStar Medical Holding Corporation (Nasdaq: ICU)...

investors.seastarmedical.com

0

2

12

SeaStarMedical

@SeaStarMedical

1 year

Dr. David Humes underscores the importance of achieving ionized calcium levels (<0.4 mmol/L) with SCD treatment. #AKI #ICU $ICU

Studies in AKI

Dr. David Humes underscores the importance of achieving ionized calcium levels (less than 0.4mmol/L) with SCD treatment and implications on clinical outcomes...

www.youtube.com

1

4

12

SeaStarMedical

@SeaStarMedical

1 year

1/17 Today we’ll be sharing the Goldstein, et al. 2021 paper on the use of the Selective Cytopheretic Device (SCD) in critically ill children, published in KIReports: #Pediatric #medicaleducation #ICU $ICU

2

6

12

SeaStarMedical

@SeaStarMedical

2 years

It was a tough year for many SPAC mergers, but SeaStar Medical was successful. According to this article, SeaStar Medical was one of the best-performing MedTech SPAC deals of 2022. #medtech #celldirectedtherapy #ICU $ICU

Resources

Read Evaluate's latest blogs, reports, webinars and thought leadership for detailed analysis of the state of the biopharma market.

www.evaluate.com

1

3

11

SeaStarMedical

@SeaStarMedical

2 years

It is with great sadness that we announce the passing of our friend and colleague, Ray Chow. Ray was a board member of SeaStar Medical and a trusted advisor and friend to us all. He will be missed Read more about Ray at

1

5

11

SeaStarMedical

@SeaStarMedical

2 years

Today, CMO, Dr. Kevin Chung, presented ‘Extracorporeal Cell Directed Therapy:Targeting the cytokine storm at the source,” at the Annual Advances in Care Conference featuring innovative therapeutics and technology for ICU patients. #ICU #CellDirectedTherapy @chungk1031 @PACLAC2

0

5

11

SeaStarMedical

@SeaStarMedical

2 years

A 22-month-old Pediatric Patient with Hemophagocytic Lymphohistiocytosis (HLH) and Multi-Organ Failure was successfully treated with SeaStar Medical's SCD.

0

3

11

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study SCD to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients #hyperinflammation #celldirectedtherapy #ICU #Kidney #AKI $ICU

SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel...

Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKR T DENVER, Jan. 09, 2023 (GLOBE NEWSWIRE) - SeaStar...

investors.seastarmedical.com

0

6

11

SeaStarMedical

@SeaStarMedical

7 months

In conclusion, SA-AKI continues to be associated with high mortality and morbidity. However, recent advancements in sub-phenotyping, biomarker-driven approaches, and clinical trial design offer opportunities to support precision medicine to help improve outcomes in this high-risk

0

2

10

SeaStarMedical

@SeaStarMedical

1 year

Next week, we will take a deeper dive into how SeaStar Medical is fighting to change these outcomes in children…stay tuned!! More at #MedTwitter #ICU #Pediatrics #kidney #MedicalDevice $ICU

Fighting the Cytokine Storm | SeaStar Medical

SeaStar Medical is advancing the science of immunomodulation to prevent the devastation of a cytokine storm

seastarmedical.com

0

3

10

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate Strategy and Near-Term Catalysts. $ICU #ICU #CytokineStorm #AcuteKidneyInjury #Hyperinflammation #AtologusCellTherapy

SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate...

– Company advancing clinically proven platform therapy , the Selective Cytopheretic Device (SCD ), to address the life-threatening consequences of hyperinflammation – SCD lead program in Acute Kidney...

investors.seastarmedical.com

0

4

10

SeaStarMedical

@SeaStarMedical

2 years

Register to hear CMO, Kevin Chung’s talk: “Extracorporeal Cell Directed Therapy:Targeting the cytokine storm at the source,” at the Annual Advances in Care Conference Jan.11-13. #medtwitter #hyperinflammation #CellDirectedTherapy @chungk1031 @PACLAC2

1

3

10

SeaStarMedical

@SeaStarMedical

1 year

Our CEO and President, Eric Schlorff, speaks with the Wall Street Analyzer in an interview on the recent significant progress of SeaStar Medical - listen HERE: #ICU $ICU #SeaStar #Medical #WallStreet

1

4

10

SeaStarMedical

@SeaStarMedical

7 months

In addition to standard “hard endpoints” like mortality and end-stage kidney disease, clinical trial endpoints for SA-AKI should also reflect patient-centered outcomes, including preservation of function, return to home, hospital-free days, activities of daily living, mental

1

2

10

SeaStarMedical

@SeaStarMedical

1 year

Here are some great shots of @slgold777 , Dr. David Humes & our own @chungk1031 in action presenting on the innovative SCD therapy at the #CCNCLondon2023 meeting last Friday.

0

4

10

SeaStarMedical

@SeaStarMedical

1 year

SeaStar Medical is proud to support the ADQI Conference on Extracorporeal Therapies, June 9-12 in Vicenza, Italy Learn more about ADQI's important initiatives at #AKI #CriticalCare #ICU $ICU

0

6

10

SeaStarMedical

@SeaStarMedical

2 years

SeaStar Medical Holding Corp (NASDAQ: ICU) CEO Eric Schlorff sits down with The Wall Street Analyzer to discuss SeaStar Medical's plans moving forward. $ICU #CellDirectedTherapy #Hyperinflammation #ICU #CriticalCare Listen to the interview:

1

4

10

SeaStarMedical

@SeaStarMedical

1 year

Hear from our very own Chief Medical Officer, Dr. Kevin Chung, on Novel Targets for Blood Purification this Friday June 9th at 2pm PST at the 7th Annual Southern California Kidney Symposium Register now for this hybrid event: #AKI #ICU $ICU

1

5

10

SeaStarMedical

@SeaStarMedical

1 year

Today, we share a tweetorial of a recent manuscript completed by members of our Scientific Advisory Board, including Drs. Stu Goldstein, Rajit Basu, David Askenazi & colleagues summarizing the clinical experience of our SCD in pediatric patients with AKI. (1 of 12)

1

4

8

SeaStarMedical

@SeaStarMedical

1 year

SeaStar Medical to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21, 2023. Sign up now: Full Press Release: #ICU #SeaStar #Hyperinflammation #CellDirectedTherapy #Kidney $ICU

0

5

10

SeaStarMedical

@SeaStarMedical

1 year

In honor of the First International Conference of Critical Care Nephrology in Children taking place in London later this month, SeaStar Medical will be sharing some key facts on pediatric acute kidney injury in the run-up to this important meeting #PedAKI #CCNC #MedTwitter

0

5

10

SeaStarMedical

@SeaStarMedical

1 year

In honor of CCNC, we’re highlighting our collaboration with conference co-chair, Stu Goldstein @slgold777 , and our Scientific Advisory Board, David Askenazi @DDD_Askenazi , Rajit Basu @BasuND22 , Theresa Mottes and David Humes

1

9

SeaStarMedical

@SeaStarMedical

1 year

In the U.S. AKI is associated with an increase in hospitalization costs estimated at between $5.4 billion and $24 billion annually (Silver SA, et al. Nephron. 2017). Find out how SeaStar Medical is fighting to change these outcomes at

Fighting the Cytokine Storm | SeaStar Medical

SeaStar Medical is advancing the science of immunomodulation to prevent the devastation of a cytokine storm

seastarmedical.com

1

5

9

SeaStarMedical

@SeaStarMedical

4 years

We are pleased to share Dr. Stuart Goldstein's publication showing the Selective Cytopheretic Device (SCD) is safe and feasible in children requiring #CRRT . The article is available now in @KIReports . @slgold777 @ASNCommunities @ASNKidney360

0

6

9

SeaStarMedical

@SeaStarMedical

1 year

SeaStar Medical is proud to announce our sponsorship of the inaugural season of the Critical Care Time podcast by co-creators Nick Mark, MD (of ICU Onepager fame!) & Cyrus Askin, MD. Learn more #CritCareTime #ICU $ICU #OnePagerICU

0

2

9

SeaStarMedical

@SeaStarMedical

2 years

Our CMO, Kevin Chung, will be at @PittHealthSci for the Department of Critical Care Medicine Grand Rounds. If you will be there, tune in at 12 PM ET today! @chungk1031 $ICU #ICU #CytokineStorm #AcuteKidneyInjury #Hyperinflammation #CellDirectedTherapy

0

4

9

SeaStarMedical

@SeaStarMedical

1 year

It was great catching up with our Scientific Advisory Board members @slgold777 @BasuND22 @AkcanArikan @DDD_Askenazi & Theresa Mottes, and leading experts such as @GistKatja & @menonshina at #CCNCLondon2023

0

5

9

SeaStarMedical

@SeaStarMedical

1 year

Today our CMO, Dr. Kevin Chung, will be delivering "Novel Targets for Blood Purification - Pathogens, Endotoxins, Neutrophils, Oh My!" for the 7th Annual Southern California Kidney Symposium at 2PM PST - tune in to hear this exciting talk! #AKI #ICU $ICU

0

1

9